Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma and extrahepatic malignancies can complicate the course of autoimmune hepatitis, and these occurrences may increase in frequency as the survival of patients with cirrhosis is extended and the prospect of new nonstandard immune-modifying intervention is realized. The frequency of hepatocellular carcinoma in patients with autoimmune hepatitis and cirrhosis is 1–9 %, and annual occurrence in patients with cirrhosis is 1.1–1.9 %. The standardized incidence ratio for hepatocellular carcinoma in autoimmune hepatitis is 23.3 (95 % confidence interval (CI) 7.5–54.3) in Sweden, and the standardized mortality ratio for hepatobiliary cancer is 42.3 (95 % CI 20.3–77.9) in New Zealand. The principal risk factor is long-standing cirrhosis, and patients at risk are characterized mainly by cirrhosis for ≥10 years, manifestations of portal hypertension, persistent liver inflammation, and immunosuppressive therapy for ≥3 years. Multiple molecular disturbances, including the accumulation of senescent hepatocytes because of telomere shortening, step-wise accumulation of chromosomal injuries, and aberrations in transcription factors and genes, may contribute to the risk. Extraheptic malignancies of diverse cell types occur in 5 % in an unpredictable fashion. The standardized incidence ratio is 2.7 (95 % CI 1.8–3.9) in New Zealand, and non-melanoma skin cancers are most common. Outcomes are related to the nature and stage of the tumor at diagnosis. Surveillance recommendations have not been promulgated, but hepatic ultrasonography every six months in patients with cirrhosis is a consideration. Routine health screening measures for other malignancies should be applied diligently.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Czaja AJ, Summerskill WH. Malignancy in chronic liver disease. Gastroenterology. 1977;73:192–193.

    PubMed  CAS  Google Scholar 

  2. Jakobovits AW, Gibson PR, Dudley FJ. Primary liver cell carcinoma complicating autoimmune chronic active hepatitis. Dig Dis Sci. 1981;26:694–699.

    Article  PubMed  CAS  Google Scholar 

  3. Burroughs AK, Bassendine MF, Thomas HC, Sherlock S. Primary liver cell cancer in autoimmune chronic liver disease. Br Med J. 1981;282:273.

    Article  CAS  Google Scholar 

  4. Bjarnason I, Magnusson B, Bjornsson S. Idiopathic chronic active hepatitis and hepatic cell carcinoma. Acta Med Scand. 1982;211:225.

    Article  PubMed  CAS  Google Scholar 

  5. Satake Y, Takada K, Ikeda K, et al. A case of primary liver cell cancer complicating lupoid hepatitis. Jpn J Med. 1988;27:83–86.

    Article  PubMed  CAS  Google Scholar 

  6. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology. 1988;8:1679–1683.

    Article  PubMed  CAS  Google Scholar 

  7. Motoo Y, Wakatsuki T, Tanaka N, et al. Resected case of hepatocellular carcinoma associated with lupoid hepatitis. J Gastroenterol Hepatol. 1989;4:295–298.

    Article  PubMed  CAS  Google Scholar 

  8. Thung SN, Bach N, Fasy TM, Jordon D, Schaffner F. Hepatocellular carcinoma associated with autoimmune chronic active hepatitis. Mt Sinai J Med. 1990;57:165–168.

    PubMed  CAS  Google Scholar 

  9. Yousuf M, Kiyosawa K, Sodeyama T, et al. Development of hepatocellular carcinoma in a man with auto-immune chronic active hepatitis. J Gastroenterol Hepatol. 1992;7:66–69.

    Article  PubMed  CAS  Google Scholar 

  10. Sakaguchi T, Nakamura S, Suzuki S, et al. Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Surg Today. 1995;25:838–842.

    Article  PubMed  CAS  Google Scholar 

  11. Yamazaki K, Kamiyama T, Shiba S, et al. An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Intern Med. 1999;38:422–425.

    Article  PubMed  CAS  Google Scholar 

  12. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222–1227.

    PubMed  CAS  Google Scholar 

  13. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology. 2004;39:1631–1638.

    Article  PubMed  Google Scholar 

  14. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944–1951.

    Article  PubMed  CAS  Google Scholar 

  15. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48:863–870.

    Article  PubMed  Google Scholar 

  16. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990;11:1044–1049.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963.

    Article  PubMed  CAS  Google Scholar 

  18. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890–897.

    Article  PubMed  CAS  Google Scholar 

  19. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005;25:734–739.

    Article  PubMed  CAS  Google Scholar 

  20. Ryder SD, Koskinas J, Rizzi PM, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology. 1995;22:718–722.

    PubMed  CAS  Google Scholar 

  21. Shi Y, Wu YH, Wu W, et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–240.

    Article  PubMed  Google Scholar 

  22. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci. 2000;45:1944–1948.

    Article  PubMed  CAS  Google Scholar 

  23. Miyake Y, Iwasaki Y, Terada R, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24:1197–1205.

    Article  PubMed  CAS  Google Scholar 

  24. Hino-Arinaga T, Ide T, Kuromatsu R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012;47:569–576.

    Article  PubMed  CAS  Google Scholar 

  25. Hardee JT, Breth GF, El-Serag HB. Hepatocellular carcinoma associated with autoimmune hepatitis. J Clin Gastroenterol. 2003;37:271–272.

    Article  PubMed  Google Scholar 

  26. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.

    Article  PubMed  CAS  Google Scholar 

  27. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348.

    Article  PubMed  CAS  Google Scholar 

  28. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984;4:136–146.

    Article  PubMed  CAS  Google Scholar 

  29. Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut. 2001;48:110–115.

    Article  PubMed  CAS  Google Scholar 

  30. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13–20.

    Article  PubMed  Google Scholar 

  31. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transpl Proc. 1969;1:106–112.

    CAS  Google Scholar 

  32. Penn I. Tumor incidence in human allograft recipients. Transpl Proc. 1979;11:1047–1051.

    CAS  Google Scholar 

  33. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol. 1981;46:459–474.

    PubMed  CAS  Google Scholar 

  34. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985;78:44–49.

    Article  PubMed  CAS  Google Scholar 

  35. Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology. 1989;10:39–43.

    Article  PubMed  CAS  Google Scholar 

  36. Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50:388–393.

    Article  PubMed  CAS  Google Scholar 

  37. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 2012;55:522–529.

    Article  PubMed  Google Scholar 

  38. Riegler JL. Preneoplastic conditions of the liver. Semin Gastrointest Dis. 1996;7:74–87.

    PubMed  CAS  Google Scholar 

  39. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311–317.

    PubMed  Google Scholar 

  40. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.

    Article  PubMed  Google Scholar 

  41. Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:16–21.

    Article  PubMed  CAS  Google Scholar 

  42. Voiculescu M, Winkler RE, Moscovici M, Neuman MG. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis. 2008;17:315–322.

    PubMed  Google Scholar 

  43. Mailey B, Buchberg B, Prendergast C, et al. A disease-based comparison of liver transplantation outcomes. Am Surg. 2009;75:901–908.

    PubMed  Google Scholar 

  44. Teixeira AC, Mente ED, Castro-e-Silva O, et al. Treatment of hepatocellular carcinoma with liver transplantation: a single-center experience from Brazil. Transpl Proc. 2010;42:502–504.

    Article  CAS  Google Scholar 

  45. Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186–194.

    Article  PubMed  CAS  Google Scholar 

  46. Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053–1063.

    Article  PubMed  Google Scholar 

  47. Gheorghe L, Iacob S, Bolog N, et al. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Rom J Gastroenterol. 2004;13:33–38.

    PubMed  Google Scholar 

  48. Nishiyama R, Kanai T, Abe J, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg. 2004;11:215–219.

    Article  PubMed  Google Scholar 

  49. Okino H, Satoh T, Watanabe J, Masumoto A, Takeda S. Hepatocellular carcinoma arising from autoimmune hepatitis: report of a case. Surg Today. 2007;37:716–718.

    Article  PubMed  Google Scholar 

  50. Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, Kimura-Hayama E. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. Ann Hepatol. 2007;6:122–126.

    PubMed  Google Scholar 

  51. Ward SC, Deniz K, Roayaie S, Qin L. Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin Liver Dis. 2008;28:123–127.

    Article  PubMed  Google Scholar 

  52. Teufel A, Weinmann A, Centner C, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578–582.

    Article  PubMed  Google Scholar 

  53. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578–585.

    Article  PubMed  Google Scholar 

  54. Yamamoto K, Hiura M, Tabaru A, et al. Rapid progression of hepatocellular carcinoma in a patient with autoimmune hepatitis. Intern Med. 2011;50:1409–1413.

    Article  PubMed  Google Scholar 

  55. Leung J, Dowling L, Obadan I, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci. 2010;55:3218–3223.

    Article  PubMed  Google Scholar 

  56. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712–2726.

    Article  PubMed  Google Scholar 

  57. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.

    Article  PubMed  CAS  Google Scholar 

  58. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des. 2011;17:3120–3140.

    Article  PubMed  CAS  Google Scholar 

  59. Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-I. Inflamm Allergy Drug Targets. 2012;11:337–350.

    Article  PubMed  CAS  Google Scholar 

  60. Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets. 2012;11:351–363.

    Article  PubMed  CAS  Google Scholar 

  61. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848–857.

    Article  PubMed  CAS  Google Scholar 

  62. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–1133.

    Article  PubMed  CAS  Google Scholar 

  63. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472.

    Article  PubMed  CAS  Google Scholar 

  64. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687–1695.

    Article  PubMed  CAS  Google Scholar 

  65. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–136.

    Article  PubMed  CAS  Google Scholar 

  66. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157:674–682.

    Article  PubMed  Google Scholar 

  67. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148.

    Article  PubMed  CAS  Google Scholar 

  68. Darwish MA, Amer AF, El-Moeity AA, Darwish NM. Association of hepatitis C virus with liver cirrhosis and hepatocellular carcinoma compared with hepatitis B virus in Egyptian patients. J Egypt Public Health Assoc. 1997;72:569–589.

    PubMed  CAS  Google Scholar 

  69. Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev. 2000;9:213–216.

    PubMed  CAS  Google Scholar 

  70. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313–333.

    PubMed  CAS  Google Scholar 

  71. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315–330.

    Article  PubMed  Google Scholar 

  72. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314–2328.

    Article  PubMed  CAS  Google Scholar 

  73. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689–700.

    Article  PubMed  Google Scholar 

  74. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149–2155.

    Article  PubMed  CAS  Google Scholar 

  75. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051–2057.

    Article  PubMed  CAS  Google Scholar 

  76. Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005;11:1862–1866.

    PubMed  Google Scholar 

  77. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.

    Article  PubMed  CAS  Google Scholar 

  78. Migita K, Watanabe Y, Jiuchi Y, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012;32:837–844.

    Article  PubMed  CAS  Google Scholar 

  79. Caballeria L, Pares A, Castells A, et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol. 2001;96:1160–1163.

    PubMed  CAS  Google Scholar 

  80. Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 1995;60:160–162.

    Article  PubMed  CAS  Google Scholar 

  81. Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125:1733–1741.

    Article  PubMed  Google Scholar 

  82. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33:647–651.

    Article  PubMed  CAS  Google Scholar 

  83. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.

    Article  PubMed  CAS  Google Scholar 

  84. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232–1240.

    Article  PubMed  Google Scholar 

  85. Poulsen LO, Thulstrup AM, Mellemkjaer L, Vilstrup H, Sorensen HT. Mortality and causes of death in patients with “lupoid hepatitis.” A long-term follow-up study in Denmark. Dan Med Bull. 2002;49:263–265.

    PubMed  Google Scholar 

  86. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413–415.

    Article  PubMed  Google Scholar 

  87. Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res. 2009;42:958–962.

    Article  PubMed  CAS  Google Scholar 

  88. Czaja AJ. Drug choices in autoimmune hepatitis: part A—steroids. Expert Rev Gastroenterol Hepatol. 2012;6:603–615.

    Article  PubMed  CAS  Google Scholar 

  89. Czaja AJ. Drug choices in autoimmune hepatitis: part B—nonsteroids. Expert Rev Gastroenterol Hepatol. 2012;6:617–635.

    Article  PubMed  CAS  Google Scholar 

  90. Watanabe T, Soga K, Hirono H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009;15:231–239.

    Article  PubMed  Google Scholar 

  91. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319–333.

    Article  PubMed  CAS  Google Scholar 

  92. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832.

    PubMed  CAS  Google Scholar 

  93. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138–1145.

    Article  PubMed  CAS  Google Scholar 

  94. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150–155.

    Article  PubMed  Google Scholar 

  95. Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study. J Natl Cancer Inst. 2011;103:1686–1695.

    Article  PubMed  Google Scholar 

  96. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539.

    Article  PubMed  CAS  Google Scholar 

  97. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–1648.

    Article  PubMed  CAS  Google Scholar 

  98. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:3036–3043.

    Article  PubMed  Google Scholar 

  99. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395–1400.

    Article  PubMed  Google Scholar 

  100. Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case–control study. Hepatol Res. 2006;36:201–208.

    Article  PubMed  CAS  Google Scholar 

  101. Montella M, Polesel J, La Vecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer. 2007;120:1555–1559.

    Article  PubMed  CAS  Google Scholar 

  102. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763.

    Article  PubMed  Google Scholar 

  103. Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL. Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;93:687–692.

    PubMed  CAS  Google Scholar 

  104. Singson RC, Fraiman M, Geller SA. Hepatocellular carcinoma with fibrolamellar pattern in a patient with autoimmune cholangitis. Mt Sinai J Med. 1999;66:109–112.

    PubMed  CAS  Google Scholar 

  105. Tapuria N, Sinha CK, Michael NG, Fisher PW. Haematogenous metastasis to ascending colon in a patient with hepatocellular carcinoma and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2007;19:607–609.

    Article  PubMed  Google Scholar 

  106. Qayyum A, Graser A, Westphalen A, et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR. 2004;183:1573–1576.

    Article  PubMed  Google Scholar 

  107. Coakley FV, Schwartz LH. Imaging of hepatocellular carcinoma: a practical approach. Semin Oncol. 2001;28:460–473.

    Article  PubMed  CAS  Google Scholar 

  108. Sahni VA, Raghunathan G, Mearadji B, et al. Autoimmune hepatitis: CT and MR imaging features with histopathological correlation. Abdom Imaging. 2010;35:75–84.

    Article  PubMed  Google Scholar 

  109. Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Large regenerative nodules in Budd–Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR. 2002;178:877–883.

    Article  PubMed  Google Scholar 

  110. Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33:437–447.

    Article  PubMed  CAS  Google Scholar 

  111. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592–1596.

    Article  PubMed  CAS  Google Scholar 

  112. Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol. 2007;21:491–500.

    PubMed  Google Scholar 

  113. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–2063.

    Article  PubMed  CAS  Google Scholar 

  114. Milazzo M, Fornari F, Gramantieri L. MicroRNA and hepatocellular carcinoma: biology and prognostic significance. Minerva Gastroenterol Dietol. 2011;57:257–271.

    PubMed  CAS  Google Scholar 

  115. Koskinas J, Petraki K, Kavantzas N, et al. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat. 2005;12:635–641.

    Article  PubMed  CAS  Google Scholar 

  116. Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992;140:859–870.

    PubMed  CAS  Google Scholar 

  117. Covini G, von Muhlen CA, Pacchetti S, et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol. 1997;26:1255–1265.

    Article  PubMed  CAS  Google Scholar 

  118. Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter. 2004;155:187–199.

    PubMed  CAS  Google Scholar 

  119. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569–573.

    Article  PubMed  CAS  Google Scholar 

  120. Blackburn EH. Telomeres. Trends Biochem Sci. 1991;16:378–381.

    Article  PubMed  CAS  Google Scholar 

  121. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol. 1992;225:951–960.

    Article  PubMed  CAS  Google Scholar 

  122. Wege H, Chui MS, Le HT, Strom SC, Zern MA. In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging. Cell Transpl. 2003;12:897–906.

    Google Scholar 

  123. Klapper W, Parwaresch R, Krupp G. Telomere biology in human aging and aging syndromes. Mech Ageing Dev. 2001;122:695–712.

    Article  PubMed  CAS  Google Scholar 

  124. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002;16:935–942.

    Article  PubMed  CAS  Google Scholar 

  125. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology. 2004;40:80–86.

    Article  PubMed  CAS  Google Scholar 

  126. Plentz RR, Schlegelberger B, Flemming P, et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology. 2005;42:522–526.

    Article  PubMed  CAS  Google Scholar 

  127. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology. 2007;45:968–976.

    Article  PubMed  CAS  Google Scholar 

  128. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20:1238–1250.

    Article  PubMed  CAS  Google Scholar 

  129. Nakagomi K, Kohwi Y, Dickinson LA, Kohwi-Shigematsu T. A novel DNA-binding motif in the nuclear matrix attachment DNA-binding protein SATB1. Mol Cell Biol. 1994;14:1852–1860.

    PubMed  CAS  Google Scholar 

  130. de Belle I, Cai S, Kohwi-Shigematsu T. The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol. 1998;141:335–348.

    Article  PubMed  Google Scholar 

  131. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419:641–645.

    Article  PubMed  CAS  Google Scholar 

  132. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34:42–51.

    Article  PubMed  CAS  Google Scholar 

  133. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–193.

    Article  PubMed  CAS  Google Scholar 

  134. Selinger CI, Cooper WA, Al-Sohaily S, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–1189.

    Article  PubMed  Google Scholar 

  135. Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–1078.

    Article  PubMed  CAS  Google Scholar 

  136. Tannapfel A, Busse C, Weinans L, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene. 2001;20:7104–7109.

    Article  PubMed  CAS  Google Scholar 

  137. Jablkowski M, Bocian A, Bialkowska J, Bartkowiak J. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clin Cancer Res. 2005;24:117–125.

    PubMed  CAS  Google Scholar 

  138. Higashitsuji H, Nagao T, Nonoguchi K, et al. A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell. 2002;2:335–346.

    Article  PubMed  CAS  Google Scholar 

  139. Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology. 2011;53:1608–1617.

    Article  PubMed  CAS  Google Scholar 

  140. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004;40:276–283.

    Article  PubMed  CAS  Google Scholar 

  141. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758–1767.

    Article  PubMed  CAS  Google Scholar 

  142. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464–468.

    Article  PubMed  CAS  Google Scholar 

  143. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003;63:5021–5027.

    PubMed  CAS  Google Scholar 

  144. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005;42:1127–1136.

    Article  PubMed  CAS  Google Scholar 

  145. Lechel A, Holstege H, Begus Y, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007;132:1465–1475.

    Article  PubMed  CAS  Google Scholar 

  146. Tseng CS, Tang KS, Lo HW, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol. 2005;100:1758–1763.

    Article  PubMed  CAS  Google Scholar 

  147. Lambert MP, Paliwal A, Vaissiere T, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54:705–715.

    Article  PubMed  CAS  Google Scholar 

  148. Longerich T, Mueller MM, Breuhahn K, et al. Oncogenetic tree modeling of human hepatocarcinogenesis. Int J Cancer. 2012;130:575–583.

    Article  PubMed  CAS  Google Scholar 

  149. Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell. 2006;9:445–457.

    Article  PubMed  CAS  Google Scholar 

  150. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.

    Article  PubMed  CAS  Google Scholar 

  151. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2011;7:16–24.

    Google Scholar 

  152. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524.

    Article  PubMed  Google Scholar 

  153. Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int. 2012;32:1120–1127.

    Article  PubMed  CAS  Google Scholar 

  154. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430.

    Article  PubMed  CAS  Google Scholar 

  155. Sherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793–796.

    Article  PubMed  Google Scholar 

  156. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802–1829.

    Article  PubMed  Google Scholar 

  157. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.

    Article  Google Scholar 

  158. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339–364.

    Article  PubMed  Google Scholar 

  159. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–474.

    Article  PubMed  Google Scholar 

  160. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350–391.

    PubMed  CAS  Google Scholar 

  161. Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–388.

    Article  PubMed  CAS  Google Scholar 

  162. Yeh CN, Lee WC, Chen MF, Tsay PK. Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol. 2003;10:916–921.

    Article  PubMed  Google Scholar 

  163. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–89.

    Article  PubMed  Google Scholar 

  164. Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl. 2012;18:315–322.

    Article  PubMed  Google Scholar 

  165. Ho CM, Lee PH, Chen CL, et al. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol. 2012;19:826–833.

    Article  PubMed  Google Scholar 

  166. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440.

    Article  PubMed  CAS  Google Scholar 

  167. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311–322.

    Article  PubMed  CAS  Google Scholar 

  168. Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382–1388.

    Article  PubMed  Google Scholar 

  169. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur J Intern Med. 2010;21:208–215.

    Article  PubMed  Google Scholar 

  170. Tateishi R, Shiina S, Ohki T, et al. Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. J Gastroenterol. 2009;44:142–146.

    Article  PubMed  Google Scholar 

  171. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78:113–124.

    Article  PubMed  Google Scholar 

  172. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569–577 (quiz 578).

    Article  PubMed  CAS  Google Scholar 

  173. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011;7:463–475.

    Article  PubMed  CAS  Google Scholar 

  174. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology. 2010;78:78–86.

    Article  PubMed  Google Scholar 

  175. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3:593–603.

    Article  PubMed  Google Scholar 

  176. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115–S120.

    Article  PubMed  Google Scholar 

  177. Xu G, Qi FZ, Zhang JH, et al. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol. 2012;10:163.

    Article  PubMed  Google Scholar 

  178. Wong KM, Yeh ML, Chuang SC, et al. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol. doi:10.1007/s12664-012-0225-x.

  179. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179–S188.

    Article  PubMed  CAS  Google Scholar 

  180. Llovet JM, Bruix J. Systematic review of randomized trials for unrespectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.

    Article  PubMed  CAS  Google Scholar 

  181. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.

    Article  PubMed  CAS  Google Scholar 

  182. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  PubMed  CAS  Google Scholar 

  183. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.

    PubMed  Google Scholar 

  184. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Int Med. 2012;156:387–389.

    Article  PubMed  Google Scholar 

  185. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child–Pugh class A cirrhosis. Am J Med. 1996;101:422–434.

    Article  PubMed  CAS  Google Scholar 

  186. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost–utility analysis. Am J Gastroenterol. 2003;98:679–690.

    Article  PubMed  Google Scholar 

  187. Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  PubMed  CAS  Google Scholar 

  188. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.

    Article  PubMed  Google Scholar 

  189. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–259.

    Article  PubMed  CAS  Google Scholar 

  190. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.

    Article  PubMed  Google Scholar 

  191. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132–141.

    Article  PubMed  Google Scholar 

  192. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154:85–93.

    Article  PubMed  Google Scholar 

  193. Milkiewicz P, Mutimer D, Hubscher SG, Elias E. Autoimmune liver disease in patients with neoplastic diseases. Eur J Gastroenterol Hepatol. 1999;11:569–573.

    Article  PubMed  CAS  Google Scholar 

  194. Cassani F, Zoli M, Baffoni L, et al. Prevalence and significance of abdominal lymphadenopathy in patients with chronic liver disease: an ultrasound study. J Clin Gastroenterol. 1990;12:42–46.

    Article  PubMed  CAS  Google Scholar 

  195. Linnell GJ, Applegate KE. Mediastinal and abdominal lymphadenopathy imitating lymphoma in an adolescent with autoimmune hepatitis. Pediatr Radiol. 2001;31:458–459.

    Article  PubMed  CAS  Google Scholar 

  196. Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study. Rheumatol Int. 2002;22:233–237.

    Article  PubMed  Google Scholar 

  197. De Block CE, De Leeuw IH, Pelckmans PA, et al. Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report. J Diabetes Complications. 2000;14:116–120.

    Article  PubMed  Google Scholar 

  198. Kondo H, Watanabe J, Iwasaki H. T-large granular lymphocyte leukemia accompanied by an increase of natural killer cells (CD3-) and associated with ulcerative colitis and autoimmune hepatitis. Leuk Lymphoma. 2001;41:207–212.

    Article  PubMed  CAS  Google Scholar 

  199. Norfleet RG, Sampson CE. Carcinoma of the cervix after treatment with prednisone and azathioprine for chronic active hepatitis. Am J Gastroenterol. 1978;70:383–384.

    PubMed  CAS  Google Scholar 

  200. Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010;85:627–629.

    Article  PubMed  CAS  Google Scholar 

  201. Lillis J, Ceilley RI, Nelson P. Merkel cell carcinoma in a patient with autoimmune hepatitis. J Drugs Dermatol. 2005;4:357–359.

    PubMed  Google Scholar 

  202. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388–3394.

    Article  PubMed  CAS  Google Scholar 

  203. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.

    Article  PubMed  CAS  Google Scholar 

  204. Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996–2010.

    Article  PubMed  CAS  Google Scholar 

  205. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.

    Article  PubMed  Google Scholar 

  206. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001;46:140–147.

    Article  PubMed  CAS  Google Scholar 

  207. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269–291.

    Article  PubMed  CAS  Google Scholar 

  208. Begley CG, Mackay IR, Bhathal PS. Another immune-mediated disease associated with hairy cell leukemia: chronic active hepatitis. Acta Haematol. 1985;73:104–105.

    Article  PubMed  CAS  Google Scholar 

  209. Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother. 1992;4:139–142.

    Article  PubMed  CAS  Google Scholar 

  210. Steegmann JL, Requena MJ, Garcia-Buey ML, et al. Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response. Am J Hematol. 1998;59:95–97.

    Article  PubMed  CAS  Google Scholar 

  211. Lebiedz P, August C, Domschke W, Schmidt HH. Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis. Eur J Intern Med. 2009;20:e3–e4.

    Article  PubMed  Google Scholar 

  212. Ko KF, Ho T, Chan KW. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry. 1995;59:558–559.

    Article  PubMed  CAS  Google Scholar 

  213. Han YS, Kim BH, Kim TH, et al. Autoimmune hepatitis in a patient with myasthenia gravis and thymoma—a report on the first case in Korea. Korean J Intern Med. 2000;15:151–155.

    PubMed  CAS  Google Scholar 

  214. Asakawa H, Kashihara T, Fukuda H, Yamamoto M. A patient with thymoma and four different organ-specific autoimmune diseases. Neth J Med. 2002;60:292–295.

    PubMed  CAS  Google Scholar 

  215. Aigner E, Strassburg CP, Strasser M, et al. Transient autoimmune hepatitis induced by a thymoma. Am J Gastroenterol. 2009;104:1332–1334.

    Article  PubMed  CAS  Google Scholar 

  216. Rodriguez-Reyna TS, Alarcon-Segovia D. Overlap syndromes in the context of shared autoimmunity. Autoimmunity. 2005;38:219–223.

    Article  PubMed  Google Scholar 

  217. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–186.

    Article  PubMed  CAS  Google Scholar 

  218. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101–113.

    Article  PubMed  CAS  Google Scholar 

  219. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691.

    Article  PubMed  Google Scholar 

  220. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–274.

    Article  PubMed  Google Scholar 

  221. Strickland FM, Kripke ML. Immune response associated with nonmelanoma skin cancer. Clin Plast Surg. 1997;24:637–647.

    PubMed  CAS  Google Scholar 

  222. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.

    Article  PubMed  CAS  Google Scholar 

  223. Han W, Ming M, He TC, He YY. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369–11377.

    Article  PubMed  CAS  Google Scholar 

  224. Han W, Soltani K, Ming M, He YY. Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis. Cancer Prev Res (Phila). 2012;5(9):1155–1162. doi:10.1158/1940-6207.CAPR-12-0185-T

  225. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385–1393.

    Article  PubMed  CAS  Google Scholar 

  226. Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13:2378–2384.

    Article  PubMed  CAS  Google Scholar 

  227. Miki D, Ochi H, Hayes CN, Aikata H, Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 2012;103:846–850.

    Article  PubMed  CAS  Google Scholar 

  228. Mizuno H, Honda M, Shirasaki T, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma. Liver Int. 2012;32:1146–1155.

    Article  PubMed  CAS  Google Scholar 

  229. Wan S, Hann HW, Myers RE, et al. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis. Liver Int. 2012;32:1233–1241.

    Article  PubMed  CAS  Google Scholar 

  230. Liu J, Yang Y, Zhang H, et al. Longer leukocyte telomere length predicts increased risk of hepatitis B virus-related hepatocellular carcinoma: a case–control analysis. Cancer. 2011;117:4247–4256.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN, 55905, USA

    Albert J. Czaja

Authors
  1. Albert J. Czaja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert J. Czaja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czaja, A.J. Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis. Dig Dis Sci 58, 1459–1476 (2013). https://doi.org/10.1007/s10620-012-2525-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2525-5

Keywords

Search

Navigation